FoxO1 - The key for the pathogenesis and therapy of acne?;FoxO1 der Schlüssel zur Pathogenese und Therapie der Akne?

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 2, 2010, Pages 105-114

  Melnik, Bodo C ^a  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

Acne; Acne therapy; Comedogenesis; FoxO1; Retinoids; Sebogenesis

Indexed keywords

ANDROGEN RECEPTOR; ANTIBIOTIC AGENT; CYTOKINE; LIVER X RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOID DERIVATIVE; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FKHR;

ACNE; ADAPTIVE IMMUNITY; CELL PROLIFERATION; DIET THERAPY; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; INSULIN RESISTANCE; INTERVENTION STUDY; LIPOGENESIS; PUBERTY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 76149121826     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07344.x     Document Type: Review

References (122)

1. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007 120 : 2479 2487.
2. Van der Heide LP, Hoekman MF, Smid MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004 380 : 297 309.
3. Rosignoli C, Nicolas JC, Jomard A, Michel S. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol 2003 12 : 480 489.
4. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The and-rogen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993 76 : 524 528.
5. Schmidt JB, Spona J, Huber J. Androgen receptor in hisutism and acne. Gynecol Obest Invest 1986 22 : 206 211.
6. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009 63 (2 142 148.
7. Lee HJ, Chang C (2003) Recent advances in androgen receptor action. Cell Mol Life Sci 60 : 1613 1622.
8. He B, Minges JT, Lee LW, Wilson EM. The FXXLF motif mediates androgen receptor-specific interactions with core-gulators. J Biol Chem 2002 277 : 10226 10235.
9. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991 266 : 510 518.
10. Ma Q, Fu W, Li P, Nicosia S V, Jenster G, Zhang X, Bai W. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocri-nol 2009 23 : 213 225.
11. Yanase T, Fan WQ. Modification of androgen receptor function by IGF-1 signaling: implications in the mechanism of refractory prostate carcinoma. Vit Horm 2009 80 : 649 666.
12. Fan WQ, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R, Nawata H. Insulin-like growth factor 1/ insulin signaling activates androgen signaling through direct interactions of Foxo 1 with androgen receptor. J Biol Chem 2007 282 : 7329 7338.
13. Nantermet P, Xu J, Yu Y, Hodor P, Holder D, Adamski S, Gentile MA, Kimmel DB, Harada S, Gerhold D, Freedman LP, Ray WJ. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem 2004 279 : 1310 1322.
14. Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 1992 99 : 509 511.
15. Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999 113 : 1011 1020.
16. Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology 1998 196 : 43 6.
17. Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis CC. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 2003 121 : 441 447.
18. Zouboulis CC, Eady A, Philpott M, Goldsmith LA, Orfanos C, Cunliffe WC, Rosenfield R. What is the pathogenesis of acne? Exp Dermatol 2005 14 : 143 152.
19. Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5α-dihydro-testosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol 2007 156 : 428 432.
20. Schmuth M, Watson RE, Deplewski D, Dubrac S, Zouboulis CC, Griffiths CE. Nuclear hormone receptors in human skin. Horm Metab Res 2007 39 : 96 105.
21. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Li-pid Res 2008 47 : 147 155.
22. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha leukotriene B4 pathway to inflammation control. Nature 1996 384 : 39 43.
23. Delerive P, Fruchart JC, Staels B. Eurosterone Meeting - Peroxisome prolife-rator activated receptors in inflammation control. J Endocrinol 2001 169 : 453 459.
24. Zouboulis ChC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005 210 : 36 8.
25. Zouboulis CC. Zileuton, a new efficient and safe anti-acne drug. Dermato-Endocrinology 2009 1 : 188 192.
26. Lee WJ, Jung HD, Lee HJ, Kim BS, Lee SJ, Kim do W. Influence of substance-P on cultured sebocytes. Arch Dermatol Res 2008 300 : 311 316.
27. Olefsy JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 2000 11 : 362 368.
28. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilkinson TM, Kliewer SA. An antidiabetic thiazolidi-nedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995 270 : 12953 12956.
29. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004 351 : 1106 1118.
30. Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator activated receptors and skin development. Hormone Res 2000 54 : 269 274.
31. Zhang Q, Seltmann H, Zouboulis CC, Konger RL. Involvement of PPAR-gamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells. J Invest Dermatol 2006 126 : 42 8.
32. Rosenfield RL, Kentsis A, Deplewski D, Ciletti N. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 1999 112 : 226 232.
33. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, Gil-liland KL, Liu W, Mauger DT, Gabbay RA, Thiboutot DM. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006 126 : 2002 2009.
34. Armoni M, Harel C, Karni S, Chen H, Bar-Yoseph F, Ver MR, Quon MJ, Karnieli E. FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 2006 281 : 19881 19891.
35. Dowell P, Otto TC, Adi S, Lane MD. Convergence of peroxisome proliferator-activated receptor gamma and Foxol signaling pathways. J Biol Chem 2003 278 : 45485 45491.
36. Fan WQ, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ, Olefsky JM. FOXOl transrepresses peroxisome pro-liferator-activated receptor γ transactivation, coordinating an insulin-induced feed-forward response in adipocytes. J Biol Chem 2009 284 : 12188 12197.
37. Vora S, Ovhal A, Jerajani H, Nair N, Chakrabortty A. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol 2008 159 : 979 995.
38. Dózsa A, Dezs B, Töth BI, Bâlint BL, Zouboulis CC, Bfró T, Remenyik E, Nagy L. PPARγ has different expression and signaling pattern in normal and pathologic sebaceous glands. J Invest Deramtol 2009 129 : S54, Abstract 319.
39. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000 16 : 459 481.
40. Russell LE, Harrison WJ, Bahta AW, Zouboulis CC, Burrin JM, Philpott MR. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol 2007 16 : 844 852.
41. Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO. LXRalpha enhances li-pid synthesis in SZ95 sebocytes. J Invest Dermatol 2008 128 : 1266 1272.
42. Swinnen JV, Ulrix W, Heyns W, Verhoeven G. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci USA 1997 94 : 12975 12980.
43. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-lc gene (SREBP-lc) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000 14 : 2819 2830.
44. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev 2000 14 : 2831 2838.
45. Joseph SB, Laffitte B, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne T F, Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002 77 : 11019 11025.
46. Seo JB, Moon HM, Kim WS, Lee YS, Jeong HW, Yoo EJ, Ham J, Kang H, Park MG, Steffensen KR, Stulnig TM, Gustafsson JA, Park SD, Kim JB. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2004 24 : 3430 3444.
47. Harrison WJ, Bull JJ, Seltmann H, Zouboulis CC, Philpott MP. Expression of lipogenic factors galectin-12, resistin, SREBP-1, and SCD in human sebaceous glands and cultured se-bocytes. J Invest Dermatol 2007 127 : 1309 1317.
48. Smith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol 2006 126 : 1226 1232.
49. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoi-nositide 3-kinase/Akt pathway. J Invest Dermatol 2008 128 : 1286 1293.
50. Kamei Y, Miura S, Suganami T, Akaike F, Kanai S, Sugita S, Katsumata A, Aburatani H, Unterman TG, Ezaki O, Ogawa Y. Regulation of SREBP1c gene expression in skeletal muscle: role of retinoid X receptor/liver X receptor and forkhead-O1 transcription factor. Endocrinology 2008 149 : 2293 2305.
51. Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch 1971 242 : 12 29.
52. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996 106 : 176 182.
53. Zvelebil MJ, MacDougall L, Leevers S, Volinia S, Vanhaesebroeck B, Gout I, Panayotou G, Domin J, Stein R, Pages F, Koga H, Salim K, Linacre J, Das P, Panaretou C, Wetzker R, Waterfield M. Structural and functional diversity of phosphoinositide 3-kinases. Philos Trans R Soc Lond B Biol Sci 1996 351 : 217 223.
54. Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 1997 8 : 313 332.
55. Carpenter CL, Cantley LC. Phosphoinositide 3-kinase and the regulation of cell growth. Biochim Biophys Acta 1996 1288 : M11 M16.
56. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, anautoinflammatory disorder. Hum Mol Genet 2002 11 : 961 969.
57. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyoge-nic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997, 72 : 611 615.
58. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory Diseases. Clinical and Genetic Advances. Arch Dermatol 2008 144 : 392 402.
59. Renn CN, Helmer A, Megahed M. Pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA syndrome). Hautarzt 2007 58 : 383 384.
60. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recom-binant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009 161 (5 1199 1201.
61. Schröder JM. Cytokine networks in the skin. J Invest Dermatol 1995 105 : 20s 24s.
62. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. J Invest Dermatol 2001 116 : 633 640.
63. Kurokawa I, Mayer-da-Silva A, Goll-nick H, Orfanos CE. Monoclonal antibody labeling for cytokeratins and filaggrin in the human pilosebaceous unit of normal, seborrhoeic and acne skin. J Invest Dermatol 1988 91 : 566 571.
64. Hughes BR, Morris C, Cunliffe WJ, Leigh IM. Keratin expression in pilose-baceous epithelia in truncal skin of acne patients. Br J Dermatol 1996 134 : 247 256.
65. Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 2009 284 : 10334 10342.
66. Hindmarsh P, Di Silvio L, Pringle PJ, Kurtz AB, Brook CGD. Changes in serum insulin concentration during puberty and their relationship to growth hormone. Clin Endocrinol 1988 21 : 381 388.
67. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991 72 : 277 282.
68. Travers SH, Labarta JI, Gargosky SE, Rosenfeld RG, Jeffers BW, Eckel RH. Insulin-like growth factor binding protein-I levels are strongly associated with insulin sensitivity and obesity in early pubertal children. J Clin Endocrinol Metab 1998 83 : 1935 1939.
69. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebae NS. Serum Insulin-like growth factor-1 in 1,030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994 78 : 744 752.
70. Caprio S. Insulin the other anabolic hormone of puberty. Acta Paediatr Suppl 1999 433 : 84 7.
71. Moran A, Jacobs DR, Steinberger J, Cohen P, Hong C-P, Prineas R, Sinaiko SR. Association between the insulin resistance of puberty and the insulin-like growth factor-1/growth hormone axis. J Clin Endocrinol Metab 2002 87 : 4817 4820.
72. Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endocrinol Metab 1995 80 : 172 178.
73. Armoni M, Harel C, Karnieli E. Transcriptional regulation of the GLUT4 gene: from PPAR-7 and FOXOl to FFA and inflammation. Trends Endocrinol Metab 2007 18 : 100 107.
74. Fan WQ, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ. FOXO 1 transrepresses peroxisome proliferator-activated receptor transactivation, coordinating an insulin-induced feedforward response in adipocytes. J Biol Chem 2009 284 : 12188 12197.
75. Jugeau S, Tenaud I, Knol AC, Jarrousse V, Quereux G, Khammari A, Dreno B. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005 153 : 1109 1113.
76. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002 169 : 1535 1541.
77. Nagy I, Pivarcsi A, Koreck A, Széll M, Urbán E, Kemény L. Distinct strains of Propionibacterium acnes indcuce selective human beta-defensin-2 and inter-leukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol 2005 124 : 931 939.
78. Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009 18 : 821 832.
79. Kim J. Review of the innate immune response in acne vulgaris: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 2005 211 : 193 198.
80. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG. Toll-like receptor 2-mediated NF-kappa B activation requires a Racl-dependent pathway. Nat Immunol 2000 1 : 533 540.
81. Chun J, Prince A. Activation of Ca2+-dependent signaling by TLR2. J Immunol 2006 177 : 1330 1337.
82. 2+ release-dependent TLR2 signaling. Am J Physiol Cell Physiol 2008 295 : 432 443.
83. Li X, Jiang S, Tapping RL. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2009 Sep 21 [Epub ahead of print].
84. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003 3 : 317 330.
85. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 2003 33 : 597 605.
86. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, Vogel SN. TLR4/ MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 2009 85 : 966 977.
87. Ruse M, Knaus UG. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol Res 2006 34 : 33 48.
88. Oeff MK, Seltmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR, Zouboulis CC. Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology 2006 213 : 266.
89. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Iwata S, Hosono O, Kawasaki H, Tanaka H, Dang NH, Morimoto C. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen presenting cells. Mol Cell Biol 2005 25 : 7743 7757.
90. Iinuma K, Sato T, Akimoto N, Noguchi N, Sasatsu M, Nishijima S, Kurokawa I, Ito A. Involvement of Propioni-bacterium acnes in the augmentation of lipogenesis in hamster sebaceous glands in vivo and in vitro. J Invest Dermatol 2009 129 : 2113 2119.
91. Suzuki N, Suzuki S, Millar DG, Unno M, Hara H, Calzascia T, Yamasaki S, Yokosuka T, Chen NJ, Elford AR, Suzuki J, Takeuchi A, Mirtsos C, Bouchard D, Ohashi PS, Yeh WC, Saito T. A critical role for the innate immune signaling molecule IRAK-4 in T cell activation. Science 2006 311 : 1927 1932.
92. Gan L, Li L. Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity. Immunol Res 2006 35 : 295 302.
93. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005 174 : 2467 2470.
94. Strauss JS, Stranieri AM, Farrell LN, Downing DT. The effect of marked inhibition of sebum production with 13cis-retinoic acid on the skin surface lipid composition. J Invest Dermatol 1980 74 : 66 7.
95. Landthaler M, Kummermehr J, Wagner A, Plewig G. Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands. Arch Derm Res 1980 269 : 297 309.
96. Peck GL, Olsen TG, Yoder FW, Strauss JS, Downing DT, Pandya M, Butkus D, Arnaud-Battandier J. Prolonged remission of cystic acne and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979 300 : 329 333.
97. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr. Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol 2009 60 : S1 S50.
98. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol 2008 9 : 369 381.
99. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis-Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006 126 : 2178 2189.
100. Layton A. The use of isotretinoin in acne. Dermato-Endocrinology 2009 1 : 162 169.
101. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Temporal changes in gene expression in the skin of patients treated with isotretinoi provide inside into its mechanism of action. Dermato-Endocrinology 2009 1 : 177 187.
102. Kim MJ, Ahn K, Park SH, Kang HJ, Jang BG, Oh SJ, Oh SM, Jeong YJ, Heo JI, Suh JG, Lim SS, Ko YJ, Huh SO, Kim SC, Park JB, Kim J, Kim JI, Jo SA, Lee JY. SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. FEBS Lett 2009 583 : 1183 1188.
103. Boudou P, Soliman H, Chivot M, Villette JM, Vexiau P, Belanger A, Fiet J. Effect of oral isotretinoin treatment on skin androgen receptor levels in male acneic patients. J Clin Endocinol Me-tab 1995 80 : 1158 1161.
104. Melnik BC, Bros U, Plewig G. Evaluation of the atherogenic risk of isotretinoin-induced and etretinate-induced alterations of lipoprotein cholesterol metabolism. J Invest Dermatol 1987 88 (3 Suppl 39s 43s.
105. Melnik B, Bros U, Plewig G. Characterization of apoprotein metabolism and atherogenic lipoproteins during oral isotretinoin treatment. Dermatologica 1987 175 (Suppl 1 158 168.
106. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, Ginsberg HN, Fleischmajer R, Brown WV. Changes in plasma lipids and lipopro-teins during isotretinoin therapy for acne. N Engl J Med 1985 313 : 981 985.
107. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008 118 : 2347 2364.
108. Kamagate A, Dong HH. FoxO1 inter-grates insulin signaling to VLDL production. Cell Cycle 2008 7 : 3162 3170.
109. Wang C, McConathy WJ, Kloer HJ, Alaupovic P. Modulation of lipopro-tein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 1998 75 : 384 390.
110. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Li-pid Res 1992 33 : 995 1003.
111. Kinnunen PKJ, Ehnholm C. Effect of serum and C apolipoproteins from very low density lipoproteins on human post-heparin plasma hepatic li-pase. FEBS Lett 1976 65 : 354 357.
112. Vu-Dac N, Gervois P, Torra I P, Fruchart JC, Kosykh V, Kooistra T, Princen HM, Dallongeville J, Staels B. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998 102 : 625 632.
113. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004 114 : 1493 1503.
114. Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. Int J Cancer 2007 121 : 2688 2692.
115. Kauppinen-Mäkelin R, Sane T, Välimäki MJ, Markkanen H, Niskanen L, Ebeling T, Jaatinen P, Juonala M the Finnish Acromegaly Study Group, Pukkala E. Increased cancer incidence in acromegaly - a nationwide survey. Clin Endocrinol (Oxf) 2009 2009 Apr 30 [Epub ahead of print].
116. Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 2002 41 (Suppl 1 S65 S83.
117. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009 19 : 398 405.
118. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germ-line mutations associated with craniosy-nostosis and skeletal dysplasia syndromes. Oncogene 2007 26 : 7158 7162.
119. Rouzier C, Soler C, Hofman P, Brenne-tot C, Bieth E, Pedeutour F. Ovarian dysgerminoma and Apert syndrome. Pediatr Blood Cancer 2008 50 : 696 698.
120. Andreou A, Lamy A, Layet V, Cailliez D, Gobet F, Pfister C, Menard M, Frebourg T. Early-onset low-grade papillary carcinoma of the bladder associated with Apert syndrome and a germline FGFR2 mutation (Pro253Arg). Am J Med Genet 2006 140 : 2245 2257.
121. Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet 2002 3 : 298 302.
122. Pollack MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 2007 86 : 820 822.